Novo Nordisk Q2 2025 Earnings: Mixed Results as GLP-1 Sales Face Headwinds

Financial Highlights

• Revenue: Consolidated revenues for Q2 were $11.68 billion, an increase of 13% year-over-year at a fixed exchange rate but a slight miss on analyst forecasts.
• Adjusted EPS: Adjusted earnings per ADR came in at $0.97, beating the consensus forecast of $0.93.
• Net Profit: Net profit increased by 22% year-over-year to DKK 55.5 billion for the first half of 2025.
• GLP-1 Sales: The Diabetes and Obesity Care segment, driven by GLP-1 products, saw a 17% increase in sales. However, growth for key drugs like Ozempic and Wegovy showed signs of deceleration.
• Wegovy Performance: Wegovy sales grew by 75%, but the growth rate slowed due to competition from compounded drugs and Eli Lilly’s competitive offerings.

Financial Performance and Forecast Comparison

Note: Revenue figures are in USD equivalent. Sales Growth is at constant exchange rates (CER).

Stock Performance and Market Reaction

Novo Nordisk’s stock has faced significant pressure, with the Q2 report and the lowered full-year guidance causing a negative market reaction.

• Initial Reaction: The stock experienced volatility, slipping on the earnings announcement day after already having tumbled in the prior week due to the pre-announced guidance cut.
• Analyst Outlook: Analysts remain cautious, with some downgrading their ratings due to concerns over competition from compounded drugs and the growing market presence of Eli Lilly.
• Guidance Cut: The company lowered its full-year sales growth forecast to a range of 8%-14%, down from the previous 13%-21%, citing slower-than-expected growth for Wegovy and Ozempic in the U.S.

Strategic Growth and Outlook

Despite the challenges, management outlined strategies to protect its market leadership and continue growth.

• Legal Action: The company is aggressively pursuing legal action against compounding pharmacies that produce unauthorized versions of its active ingredient, semaglutide.
• Direct-to-Consumer: Novo Nordisk is expanding its direct-to-patient initiatives, including the NovoCare Pharmacy platform, to better control distribution and combat illegal alternatives.
• Market Access: A major win was securing exclusive coverage for Wegovy on the CVS National Template Formulary, which went into effect on July 1, 2025.

Executive Commentary

“While delivering strong sales growth in the first half of 2025, we have lowered our full-year outlook due to lower growth expectations for our GLP-1 treatments in the second half of 2025,” said Lars Fruergaard Jørgensen, President and CEO. “We are confident in our long-term strategy and will continue to invest in our production capacity, R&D, and commercial efforts to meet the significant demand for our innovative treatments.”